Cara Therapeutics Inc (NASDAQ:CARA) shares fell 0% on Thursday . The stock traded as low as $12.56 and last traded at $12.77. 1,396,929 shares were traded during trading, an increase of 64% from the average session volume of 854,225 shares. The stock had previously closed at $12.77.

Several research firms have weighed in on CARA. Stifel Nicolaus reaffirmed a “buy” rating and set a $17.00 price target on shares of Cara Therapeutics in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Cara Therapeutics in a research report on Wednesday, October 4th. ValuEngine lowered Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. BidaskClub raised Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 2nd. Finally, Zacks Investment Research lowered Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Cara Therapeutics presently has an average rating of “Buy” and a consensus target price of $24.97.

The company has a market capitalization of $416.41, a price-to-earnings ratio of -5.58 and a beta of 2.96.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). During the same period last year, the business earned ($0.42) earnings per share. analysts forecast that Cara Therapeutics Inc will post -1.84 earnings per share for the current fiscal year.

In related news, CEO Derek T. Chalmers sold 16,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $12.66, for a total transaction of $202,560.00. Following the transaction, the chief executive officer now directly owns 1,066,292 shares of the company’s stock, valued at approximately $13,499,256.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Cara Therapeutics by 17.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,107,874 shares of the biopharmaceutical company’s stock worth $17,050,000 after acquiring an additional 164,247 shares during the last quarter. Gotham Asset Management LLC bought a new stake in Cara Therapeutics in the 2nd quarter valued at $448,000. C WorldWide Group Holding A S boosted its stake in Cara Therapeutics by 76.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 291,341 shares of the biopharmaceutical company’s stock valued at $3,988,000 after purchasing an additional 126,330 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Cara Therapeutics in the 3rd quarter valued at $451,000. Finally, Swiss National Bank bought a new stake in Cara Therapeutics in the 2nd quarter valued at $651,000. 58.64% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Cara Therapeutics (CARA) Trading Down 0%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/05/cara-therapeutics-cara-trading-down-0.html.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Receive News & Stock Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related stocks with our FREE daily email newsletter.